Jack K. Allen, CFA, Senior Research Analyst with Baird, said Regeneron—whose shares dipped 1% on Tuesday–may not be done with smaller “bolt-on” acquisitions. He speculated that the buyer may be interested as well in buying another of its collaboration partners—Decibel Therapeutics (DBTX), with which Regeneron is partnering to discover and develop gene therapies for hearing loss. The companies began partnering in November 2017 and extended the partnership last November for another two years . . .
The post StockWatch: Checkmate Shares Quadruple on Regeneron Buyout appeared first on GEN – Genetic Engineering and Biotechnology News.